Injectable biologics remain the standard of care across many chronic, pediatric, and geriatric indications, spanning a broad range of modalities including peptides, proteins, monoclonal antibodies, vaccines, enzymes, and other complex biologics. However, long-term reliance on injections often results in treatment fatigue, poor adherence, injection-site complications, and reduced quality of life. These challenges are particularly pronounced for patients requiring lifelong therapy, such as those with metabolic, endocrine, autoimmune, and rare diseases. The growing diversity and complexity of biologic therapeutics further amplifies the need for patient-centric delivery approaches. Together, these limitations underscore a significant unmet need for advanced oral biologic platforms and next-generation delivery solutions capable of enabling safe, effective, and convenient administration across multiple biologic modalities. CuriOralRx’s platform technology is designed to overcome these limitations and unlock the full therapeutic potential of biologics through safe, effective, and patient-centric oral delivery across multiple modalities.